Industry Watch

2010 ◽  
Vol 14 (02) ◽  
pp. 21-35
Keyword(s):  
Drug Delivery ◽  
Strategic Alliance ◽  
Research Collaboration ◽  
Life Sciences ◽  
Consumer Health ◽  
Start Up ◽  
Otsuka Pharmaceutical ◽  
Development Agreement ◽  
Screening Services ◽  
Cd4 Testing

Patrys to Work with CSL to Explore Antibody Drugs. Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals. Sanofi, Minsheng in China Consumer Health Venture. Biocon Signs MoU with Malaysia's BiotechCorp. Biocon, Bayer Tie up to Fight Diabetes in India. Ranbaxy to Acquire Bangalore Based Biovel Life Sciences. DiscoveRx, Jubilant Biosys Announce Agreement for Screening Services. BD Biosciences Collaborates with ReaMetrix to Develop New, Affordable CD4 Testing Products to Help Fight HIV/AIDS in Developing Countries. Aegis Therapeutics and Dr. Reddy's Announce Strategic Alliance. Penwest Enters Into Research and Development Agreement with Otsuka Pharmaceutical. AstraZeneca and CrystalGenomics Form Research Collaboration to Develop Novel Anti-Infective Treatments. International and Local Recognition for Singaporean Biotech Start-up – Curiox Biosystems. Roche Establishes New Medical Research Hub in Singapore. Virbac Unveils First Regional R&D Center in Asia.

Industry Watch

2007 ◽  
Vol 11 (10) ◽  
pp. 634-653
Keyword(s):  
Drug Delivery ◽  
Cervical Cancer ◽  
Liver Cancer ◽  
Phage Therapy ◽  
Life Sciences ◽  
Screening Tests ◽  
Manufacturing Plant ◽  
Phase 2 ◽  
Cancer Trial ◽  
Manufacturing Facility

Nanotechnology Victoria Sets to Revolutionize Drug Delivery. Polartechnics Commences Truscreen Cervical Cancer Sensor for International Trade. Protagen and ZAP Collaborates with Beijing Proteome Research Center to Develop Antibodies. Albany Molecular Research to Acquire Manufacturing Facilities in India. NeoGen Labs to Launch Screening Tests to Detect IEMs in Babies. Pall Opens New Center of Excellence in India to Serve Life Sciences Market. Sun Pharma to Buy Taro for US$454 Million. Wockhardt Acquires Negma Laboratories in France. Eisai Obtains Favor with Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr Reddy's Laboratories. Japan's Bioventures Today — ProteinExpress Co., Ltd. Special Phage Services Signs Agreement with Wako for Phage Therapy. Affymetrix Opens its First Manufacturing Facility in Singapore. Bio-Rad Builds Manufacturing Plant in Singapore. West Pharmaceutical Services Invests US $30 Million in Singapore Facility. Progen Announces Phase 2 Liver Cancer Trial.

BIOBOARD

2013 ◽  
Vol 17 (03) ◽  
pp. 5-23
Keyword(s):  
United States ◽  
United Kingdom ◽  
Strategic Alliance ◽  
Research Collaboration ◽  
Therapeutic Vaccine ◽  
The Philippines ◽  
Age Related Macular Degeneration ◽  
Asia Pacific ◽  
Age Related ◽  
National Cancer Research Institute

AUSTRALIA – Well-known antibiotic amoxycillin found to be ineffective cough treatment. AUSTRALIA – Bring the noise: has technology made us scared of silence? INDIA – Biocon receives marketing authorization for novel biologic itolizumab for psoriasis. ISRAEL – Aspireo reports Somatoprim Phase Ib interim data. JAPAN – Daiichi Sankyo and Amplimmune announce strategic alliance to develop AMP-110 therapy for autoimmune disease. JAPAN – Eisai signs agreement with Epizyme and Roche Molecular Systems to develop companion diagnostic. THE PHILIPPINES – Asia-Pacific Analysis: The growth of stem-cell therapy. THE PHILIPPINES – Is the world ready for scientific diplomacy? UNITED KINGDOM – ARIAD and the U.K. National Cancer Research Institute to collaborate on SPIRIT 3 clinical study. UNITED KINGDOM – Vision research collaboration on novel treatment for wet age-related macular degeneration. UNITED STATES – Reducing medical mistakes: Two recently published studies support the use of DNA testing on biopsy samples to prevent misdiagnoses. UNITED STATES – CoDa Therapeutics reports positive results from Phase IIb Study of NEXAGON® in chronic venous leg ulcers. UNITED STATES – Inovio Pharmaceuticals to initiate clinical trial for its hepatitis C therapeutic vaccine later this year. UNITED STATES – Jolt to brain eases pain without drugs. UNITED STATES – Can a new vaccine prevent colon cancer? UNITED STATES – Immunovaccine's DPX-Survivac produces sustained, dose related immune responses in Phase I ovarian cancer study.

Company News

2001 ◽  
Vol 05 (14) ◽  
pp. 291-301
Keyword(s):  
Medical Devices ◽  
Strategic Alliance ◽  
State Of The Art ◽  
Life Sciences ◽  
Medical Products ◽  
First Order ◽  
Commercial Use ◽  
Sign Distribution ◽  
Wastewater Recycling ◽  
Set Up

Cell Robotics' Medical Devices Well Received in China. US National Nutritional Foods Association and China's Sanjiu Pharmaceutical Establish Historic Partnership. Novacor LVAS Approved for Commercial Use in Japan. NOMOS and Lynmed to Jointly Distribute Medical Products in China and HK. Eli Lilly to Buy Out Ranbaxy's Stake. US-based Dragon Expands Business in Hong Kong and China. Australia's Global Doctor and US MedAire Announce Strategic Alliance. Taiwan's Gene Born Biotech Corp Adopts Thermogenesis's BioArchive System. Cepheid and BioSynTech Sign Distribution Agreement To Enter Life Sciences Research Market in Southeast Asia. Harbin Pharmaceutical Completes China's Largest Antibiotic Wastewater Recycling Project. Eli Lilly to Set Up State-of-the-Art Systems Biology R&D Center in Singapore. Varian Receives First Order for World's Most Powerful NMR Spectrometer from Japan.

ACADEMIC ENTREPRENEURSHIP IN LIFE SCIENCES: THE CASE OF A MODERATE INNOVATOR COUNTRY

2016 ◽  
Vol 21 (01) ◽  
pp. 1650004 ◽  
Author(s):  
AURORA A. C. TEIXEIRA ◽  
JOÃO NOGUEIRA
Keyword(s):  
Empirical Evidence ◽  
Academic Entrepreneurship ◽  
Life Science ◽  
Life Sciences ◽  
Econometric Analysis ◽  
Business Community ◽  
Entrepreneurial Activity ◽  
Academic World ◽  
Research Institutes ◽  
Start Up

The commercialization of research done by universities and research institutes is seen as a key element of entrepreneurship, justifying a better understanding of the entrepreneurial process within those institutions. Despite efforts in recent decades, there remains a widespread ignorance about who are the individuals with a greater vocation for research and marketing of knowledge. Focusing on a relatively unexplored context — the field of life sciences in a moderate innovator country, Portugal — this study adds new empirical evidence to the precedents of academic entrepreneurship. The results, based on 247 responses, evidence that entrepreneurship (including patent production, consultancy work and creation of start-up companies) is still very incipient. The econometric analysis of the “Index of entrepreneurial activity,” shows that: (1) the phenomenon of academic entrepreneurship is within everyone’s reach, but embraced by very few; and (2) academic entrepreneurship feeds on the exchange of knowledge and resources among universities and research institutes and their socio-economic environment. Thus, to increase academic entrepreneurship in life science in Portugal, the mechanisms to facilitate the interactions between universities and the business community must be strengthened, promoting the development of business clusters with the integration of the academic world, which will enable the transformation of knowledge into market products and services.

Achieving optimal licensing, strategic alliance and financing outcomes via experienced intermediaries!

2011 ◽  
Vol 18 (2) ◽  
Author(s):  
Benjamin P Chen
Keyword(s):  
Strategic Alliances ◽  
Strategic Alliance ◽  
Innovative Product ◽  
Strategic Partnerships ◽  
Time Experience ◽  
Start Up ◽  
Selection Of

Financial and technical resources from strategic partnerships (licensing and strategic alliances) represent vital resources for entrepreneurs to support the development of innovative product opportunities. Success completion of an impactful partnership for a start-up takes time, experience and skills. The key focus of this article is to outline for entrepreneurs the values that intermediaries can offer in achieving partnering/financing objectives. Entrepreneurs will gain insight on services offered by intermediaries, choices and selection of intermediaries as well as expectation for intermediaries to ensure best outcome.

IT IS NOW OR NEVER; FOR ENHANCED RESEARCH COLLABORATION, NAY, PARTNERSHIPS BETWEEN INDUSTRY AND INSTITUTES/ACADEMIA

INDIAN DRUGS ◽  
2021 ◽  
Vol 58 (4) ◽  
pp. 5-6
Author(s):  
Gopakumar G. Nair ◽  
Keyword(s):  
Patent Protection ◽  
Research Collaboration ◽  
Technology Licensing ◽  
National Chemical Laboratory ◽  
Chemical Laboratory ◽  
Innovative Research ◽  
Box Office ◽  
Start Up ◽  
Short Time ◽  
Made In

Pens have gone dry and words have run out, highlighting the need for Industry-Academia collaboration. However, it is indeed deeply dismaying that very little progress has been made in “building the bridges” we have been advocating and promoting over the last few decades, when the necessity and urgency of innovative research leading to IP/Patent protection and technology licensing is recognised as a priority. Except for couple of pockets of excellence, there have been very few “box office” hits to write about. One example to quote is the Venture Centre at the NCL (National Chemical Laboratory, Pune) headed by Dr. V. Premnath. A few exceptional achievements in a relatively short time by this innovation/start up incubation centre are worth taking note of.

scholarly journals Researchers collaborate with same-gendered colleagues more often than expected across the life sciences

2018 ◽  
Author(s):  
Luke Holman ◽  
Claire Morandin
Keyword(s):  
Human Capital ◽  
Research Collaboration ◽  
Life Sciences ◽  
Scientific Progress ◽  
High Impact ◽  
High Impact Factor ◽  
Gender Imbalance ◽  
Women In Academia ◽  
Academic Workforce ◽  
Mixed Gender

AbstractEvidence suggests that women in academia are hindered by conscious and unconscious biases, and often feel excluded from formal and informal opportunities for research collaboration. In addition to ensuring fairness and helping to redress gender imbalance in the academic workforce, increasing women’s access to collaboration could help scientific progress by drawing on more of the available human capital. Here, we test whether researchers tend to collaborate with same-gendered colleagues, using more stringent methods and a larger dataset than in past work. Our results reaffirm that researchers co-publish with colleagues of the same gender more often than expected by chance, and show that this ‘gender homophily’ is slightly stronger today than it was 10 years ago. Contrary to our expectations, we found no evidence that homophily is driven mostly by senior academics, and no evidence that homophily is stronger in fields where women are in the minority. Interestingly, journals with a high impact factor for their discipline tended to have comparatively low homophily, as predicted if mixed-gender teams produce better research. We discuss some potential causes of gender homophily in science.

Sign in / Sign up

Export Citation Format

Share Document